Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MGTX - MeiraGTx Holdings plc


IEX Last Trade
4.08
-0.100   -2.451%

Share volume: 108,952
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$4.18
-0.10
-2.39%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
6%
Profitability 0%
Dept financing 16%
Liquidity 44%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
-2.40%
1 Month
-17.28%
3 Months
-18.44%
6 Months
-33.61%
1 Year
-32.50%
2 Year
-51.89%
Key data
Stock price
$4.08
P/E Ratio 
-2.84
DAY RANGE
N/A - N/A
EPS 
-$1.49
52 WEEK RANGE
$3.49 - $7.60
52 WEEK CHANGE
-$0.36
MARKET CAP 
264.139 M
YIELD 
N/A
SHARES OUTSTANDING 
64.899 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
BETA 
1.85
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$133,489
AVERAGE 30 VOLUME 
$205,181
Company detail
CEO: Alexandria Forbes
Region: US
Website: http://meiragtx.com/
Employees: 347
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.

Recent news